Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Guido Oelkers
Age : 57
Public asset : 7,623,262 USD
Country of residence : Unknown
Linked companies : Swedish Orphan Biovitrum AB (publ) - Dova Pharmaceuticals, Inc.

Biography of Guido Oelkers 
Guido Oelkers is a businessperson who has been at the helm of 8 different companies. Dr. Oelkers is President & Chief Executive Officer for Swedish Orphan Biovitrum AB, Chief Executive Officer of BSN medical BV and Chief Executive Officer & Director at BSN medical International Holding GmbH & Co. KG. He is also on the board of Dova Pharmaceuticals, Inc. and Swedish Orphan Biovitrum, Inc. In the past Guido Oelkers occupied the position of Group Chief Executive Officer of BSN medical GmbH, Chief Executive Officer at BSN Medical Holding, President & Chief Executive Officer at Gambro AB, President & Chief Executive Officer for Gambro Lundia AB, Chief Executive Officer of Invida Group Pte Ltd., Executive Vice President-Commercial Operations at Takeda A, Principal at Aventis Pharma Deutschland GmbH and Executive Vice President-Commercial Operations at Takeda Pharmaceuticals International GmbH. Dr. Oelkers received a doctorate from the University of South Australia and a graduate degree from London South Bank University.


Current positions of Guido Oelkers 
Holdings of Guido Oelkers 
Guido Oelkers : Personal Network 
Most Read News 
09/13Ark's Cathie Wood calls Fed hikes a mistake and preps for deflation
RE
09/26Unilever's soap opera: M&A, Nelson Peltz, CEO to retire
RE
09/20JPMorgan CEO Dimon to warn Congress of economic 'storm clouds' -testimony
RE
09/14Package that exploded in Boston had note critical of Meta's Zuckerberg, CNN reports
RE
09/13Inditex founder Amancio Ortega to buy U.S. warehouses for $905 million
RE
09/26Twitter to interview Elon Musk, known for combative testimony
RE
09/21Trump ally Barrack's trial on foreign agent charges moves to opening statements
RE
09/20Palihapitiya to wind down two blank-check firms as choppy markets deter valuations
RE
09/21Bloomberg to spend $85 million against U.S. plastic, petrochem buildout
RE
09/14Kuehne: have raised stake in Lufthansa to 17.5%
RE
More news


© 2022 People and Ownership :   
Guido Oelkers : Connections 


Latest news about Guido Oelkers 
07/19Transcript : Swedish Orphan Biovitrum AB, Q2 2022 Earnings Call, Jul 19, 2022
CI
04/28Transcript : Swedish Orphan Biovitrum AB, Q1 2022 Earnings Call, Apr 28, 2022
CI
02/10Transcript : Swedish Orphan Biovitrum AB, Q4 2021 Earnings Call, Feb 10, 2022
CI
2021Swedish Orphan Biovitrum AB Announces Executive Changes
CI
2021Advent International Corporation and GIC Special Investments Pte. Ltd. cancelled the acquisition of Swedish Orphan Biovitrum AB (OM:SOBI) from Investor AB (OM:INVE A), AP Fonden 4 and others.
CI
2021Advent International Corporation and GIC Special Investments Pte. Ltd. made an offer to acquire Swedish Orphan Biovitrum AB (OM:SOBI) from Investor AB (OM:INVE A), AP Fonden 4 and others for SEK 69.4 billion.
CI
2021Transcript : Swedish Orphan Biovitrum AB, Q2 2021 Earnings Call, Jul 21, 2021
CI
More news